Media aren't welcome at Boston Scientific's annual shareholder meeting today, the first since J. Raymond Elliott became CEO of the device maker. Boston Scientific has also been wrestling with a number of other problems. Last month the Department of Justice rejected the company's plea deal related to Guidant's concealment of safety issues with its heart device. Earlier this year BS reached a $1.7 billion patent dispute settlement with rival Johnson & Johnson, and also announced that it would cut 1,300 jobs as part of a worldwide restructuring effort. Last quarter the company reported a loss of $1.6 billion. Report